Gliomas

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

More than 18,000 people were diagnosed with and more than 13,000 died from primary brain tumors in 2003.1 The most common of the primary brain tumors is gliomas. Depending on the grade and morphologic type of glioma, newly diagnosed patients receive watchful waiting, surgical resection, radiotherapy, or chemotherapy, or some combination of these therapies. Regardless of therapy, most patients will progress and have a high risk of mortality and reduced quality of life. Thus, there has been intense interest in understanding the biology and genetics of gliomas, to provide better diagnostic tools and new therapeutic approaches. Molecular pathology markers are being identified that have been or will soon prove to be clinically useful in the practice of clinical neurooncology (see Table 27-1).

Original languageEnglish (US)
Title of host publicationMolecular Pathology in Clinical Practice
PublisherSpringer New York
Pages299-304
Number of pages6
ISBN (Print)038733226X, 9780387332260
DOIs
StatePublished - 2007

Fingerprint

Glioma
Brain Neoplasms
Watchful Waiting
Molecular Pathology
Radiotherapy
Therapeutics
Quality of Life
Drug Therapy
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Jenkins, R. B. (2007). Gliomas. In Molecular Pathology in Clinical Practice (pp. 299-304). Springer New York. https://doi.org/10.1007/978-0-387-33227-7_27

Gliomas. / Jenkins, Robert Brian.

Molecular Pathology in Clinical Practice. Springer New York, 2007. p. 299-304.

Research output: Chapter in Book/Report/Conference proceedingChapter

Jenkins, RB 2007, Gliomas. in Molecular Pathology in Clinical Practice. Springer New York, pp. 299-304. https://doi.org/10.1007/978-0-387-33227-7_27
Jenkins RB. Gliomas. In Molecular Pathology in Clinical Practice. Springer New York. 2007. p. 299-304 https://doi.org/10.1007/978-0-387-33227-7_27
Jenkins, Robert Brian. / Gliomas. Molecular Pathology in Clinical Practice. Springer New York, 2007. pp. 299-304
@inbook{44fafc318d944b81b4d299f5165f74a4,
title = "Gliomas",
abstract = "More than 18,000 people were diagnosed with and more than 13,000 died from primary brain tumors in 2003.1 The most common of the primary brain tumors is gliomas. Depending on the grade and morphologic type of glioma, newly diagnosed patients receive watchful waiting, surgical resection, radiotherapy, or chemotherapy, or some combination of these therapies. Regardless of therapy, most patients will progress and have a high risk of mortality and reduced quality of life. Thus, there has been intense interest in understanding the biology and genetics of gliomas, to provide better diagnostic tools and new therapeutic approaches. Molecular pathology markers are being identified that have been or will soon prove to be clinically useful in the practice of clinical neurooncology (see Table 27-1).",
author = "Jenkins, {Robert Brian}",
year = "2007",
doi = "10.1007/978-0-387-33227-7_27",
language = "English (US)",
isbn = "038733226X",
pages = "299--304",
booktitle = "Molecular Pathology in Clinical Practice",
publisher = "Springer New York",

}

TY - CHAP

T1 - Gliomas

AU - Jenkins, Robert Brian

PY - 2007

Y1 - 2007

N2 - More than 18,000 people were diagnosed with and more than 13,000 died from primary brain tumors in 2003.1 The most common of the primary brain tumors is gliomas. Depending on the grade and morphologic type of glioma, newly diagnosed patients receive watchful waiting, surgical resection, radiotherapy, or chemotherapy, or some combination of these therapies. Regardless of therapy, most patients will progress and have a high risk of mortality and reduced quality of life. Thus, there has been intense interest in understanding the biology and genetics of gliomas, to provide better diagnostic tools and new therapeutic approaches. Molecular pathology markers are being identified that have been or will soon prove to be clinically useful in the practice of clinical neurooncology (see Table 27-1).

AB - More than 18,000 people were diagnosed with and more than 13,000 died from primary brain tumors in 2003.1 The most common of the primary brain tumors is gliomas. Depending on the grade and morphologic type of glioma, newly diagnosed patients receive watchful waiting, surgical resection, radiotherapy, or chemotherapy, or some combination of these therapies. Regardless of therapy, most patients will progress and have a high risk of mortality and reduced quality of life. Thus, there has been intense interest in understanding the biology and genetics of gliomas, to provide better diagnostic tools and new therapeutic approaches. Molecular pathology markers are being identified that have been or will soon prove to be clinically useful in the practice of clinical neurooncology (see Table 27-1).

UR - http://www.scopus.com/inward/record.url?scp=84889979667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889979667&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-33227-7_27

DO - 10.1007/978-0-387-33227-7_27

M3 - Chapter

SN - 038733226X

SN - 9780387332260

SP - 299

EP - 304

BT - Molecular Pathology in Clinical Practice

PB - Springer New York

ER -